In the first quarter of this year, there was a significant decline in the number of novel drugs approved, with only seven receiving approval compared to thirteen in the same period last year.However, analyzing the trend month by month, April 2023 stood out with only one novel drug passing muster with the FDA, indicating a particularly dry period. Will April 2024 see a continuation of this trend or a potential shift towards increased approvals?